Clinical Trial Update: A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating higher-dose abiraterone acetate in castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Terence Friedlander, MD | Conditions: Castration Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-08-17